0001209191-24-000929.txt : 20240104
0001209191-24-000929.hdr.sgml : 20240104
20240104213545
ACCESSION NUMBER: 0001209191-24-000929
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZANTE GREG
CENTRAL INDEX KEY: 0001264949
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 24514324
MAIL ADDRESS:
STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100
STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD,
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-03
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001264949
ZANTE GREG
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
0
Common Stock, par value $0.00001 per share
2024-01-03
4
A
0
28334
0.00
A
188724
D
Common Stock, par value $0.00001 per share
2024-01-03
4
F
0
18233
17.40
D
170491
D
Common Stock, par value $0.00001 per share
2024-01-03
4
A
0
70000
0.00
A
240491
D
Common Stock, par value $0.00001 per share
2024-01-03
4
F
0
30889
17.40
D
209602
D
Common Stock, par value $0.00001 per share
2024-01-04
4
F
0
13872
18.58
D
195730
D
Common Stock, par value $0.00001 per share
2024-01-04
4
S
0
15000
17.90
D
180730
D
Stock Option (Right to Buy)
17.40
2024-01-03
4
A
0
155000
0.00
A
2025-01-03
2034-01-03
Common Stock
155000
155000
D
The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal.
Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon
the vesting of certain shares of common stock subject to certain performance restricted stock units.
Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.
25% of the shares subject to the option will vest on each anniversary of the grant date.
/s/ Michael Morneau, as Attorney-in-Fact
2024-01-04